Coherus Oncology (CHRS) EBIT (QoQ) (2013 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EBIT (QoQ) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.57% |
| Mar 31, 2026 | 21.21% |
| Dec 31, 2025 | -3.49% |
| Sep 30, 2025 | 2.53% |
| Jun 30, 2025 | -0.11% |
| Mar 31, 2025 | -0.11% |
| Dec 31, 2024 | 3.14% |
| Sep 30, 2024 | -18.25% |
| Jun 30, 2024 | 41.54% |
| Mar 31, 2024 | 1.62% |
| Dec 31, 2023 | -115.29% |
| Sep 30, 2023 | 7.34% |
| Jun 30, 2023 | 49.01% |
| Mar 31, 2023 | -31.56% |
| Dec 31, 2022 | 35.99% |
| Sep 30, 2022 | -82.78% |
| Jun 30, 2022 | 45.61% |
| Mar 31, 2022 | -104.63% |
| Dec 31, 2021 | -20.62% |
| Sep 30, 2021 | -35.69% |